Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies

Uwe Platzbecker1*, Joerg Chromik2, Jan Krönke3, Hiroshi Handa4, Stephen Strickland5, Yasushi Miyazaki6, Martin Wermke7, Wataru Sakamoto8, Yoshifumi Tachibana9, Tillmann Taube10 and Ulrich Germing11

Abstract

Background: This report summarizes three phase I studies evaluating volasertib, a polo-like kinase inhibitor, plus azacitidine in adults with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia.

Methods: Patients received intravenous volasertib in 28-day cycles (dose-escalation schedules). In Part 1 of 1230.33 (Study 1; NCT01957644), patients received 250–350 mg volasertib on day (D)1 and D15; in Part 2, patients received different schedules [A, D1: 170 mg/m²; B, D7: 170 mg/m²; C, D1 and D7: 110 mg/m²]. In 1230.35 (Study 2; NCT02201329), patients received 200–300 mg volasertib on D1 and D15. In 1230.43 (Study 3; NCT02721875), patients received 110 mg/m² volasertib on D1 and D8. All patients in Studies 1 and 2, and approximately half of the patients in Study 3, were scheduled to receive subcutaneous azacitidine 75 mg/m² on D1–7.

Results: Overall, 22 patients were treated (17 with MDS; 12 previously untreated). Across Studies 1 and 2 (n = 21), the most common drug-related adverse events were hematological (thrombocytopenia [n = 11]; neutropenia [n = 8]). All dose-limiting toxicities were grade 4 thrombocytopenia. The only treated patient in Study 3 experienced 18 adverse events following volasertib monotherapy. Studies 1 and 2 showed preliminary activity (objective response rates: 25 and 40%).

Conclusions: The safety of volasertib with azacitidine in patients with MDS was consistent with other volasertib studies. All studies were terminated prematurely following the discontinuation of volasertib for non-clinical reasons by Boehringer Ingelheim; however, safety information on volasertib plus azacitidine are of interest for future studies in other diseases.

Keywords: Volasertib, Phase I, Myelodysplastic syndrome, Chronic myelomonocytic leukemia, Acute myeloid leukemia

Introduction

Myelodysplastic syndromes (MDS), chronic myelomonocytic leukemias (CMML), and acute myeloid leukemias (AML) are related myeloid malignancies characterized by
hematopoietic insufficiency, affecting clonal hematopoietic stem cells. Patients with MDS, CMML, and AML can receive risk-adapted treatment, including curative hematological stem cell transplantation (HSCT), palliative hypomethylating agents, and chemotherapy [1–3].

Volasertib is a potent, selective, small molecule inhibitor of Polo-like kinases (PLK) PLK1, PLK2, and PLK3 [4]. PLK1, a member of the PLK family, controls essential steps during mitosis and its activity peaks during late G2 and M phases. It is highly expressed in proliferating cells, and is overexpressed in a broad spectrum of cancers, making it a potential target for anti-cancer therapy [4].

Hypomethylating agents, such as azacitidine and decitabine, are potent inhibitors of DNA methyltransferase that function to restore normal cell growth and differentiation [5]. These therapies are recommended for patients with MDS and AML who are not suitable for HSCT [6, 7]. A randomized phase III trial in patients with AML (n = 488) showed that azacitidine improved overall survival and was more effective than conventional care regimens [8]. However, positive outcomes with azacitidine remain limited and short-lived in the majority of patients [7]. There are virtually no predictive parameters for response to hypomethylating agents, and the treatment response rate is approximately 50% [7, 9]. Therefore, there is a strong medical need for the development of novel therapies.

The combination of a drug that interferes with cell cycle progression or S phase (e.g., azacitidine) with volasertib might be expected to produce additive or synergistic effects. The additive activity of the combination of volasertib and azacitidine was confirmed in preclinical studies in AML cells [10].

Volasertib showed clinical activity in a phase I/II study in adult patients with relapsed/refractory AML [11], and in combination with low-dose cytarabine (LDAC) in adult patients with AML unsuitable for intensive treatment [12]. However, a phase III study (POLO-AML-2; NCT01721876), conducted to confirm the promising phase I/II results, evaluating volasertib and LDAC in previously untreated patients aged ≥ 65 years with AML who were ineligible for intensive therapy, did not meet its primary endpoint [13].

Combining volasertib with an agent that has a different mechanism of action, such as azacitidine, was therefore considered a rational treatment approach for evaluation in the treatment of patients with MDS, AML, and CMML.

This report summarizes the design and results of three phase I studies that were conducted to determine the safety, tolerability, and preliminary anti-cancer activity of volasertib monotherapy and in combination with azacitidine in adults with MDS, CMML, or AML. Although the global clinical development of volasertib by Boehringer Ingelheim was discontinued for non-clinical reasons in December 2016 while these studies were ongoing, published information on the safety of volasertib in combination with azacitidine in this patient population may be of scientific interest [14]. Of note, the current licensing agreement is not limited to clinical development to pediatrics, and development in adults might be considered in the future.

Methods
Study design and patients
This report covers three open-label, phase I, dose-escalation studies investigating volasertib monotherapy and combination therapy with azacitidine in adult patients with MDS, AML, and/or CMML: studies 1230.33 (Study 1), 1230.35 (Study 2), and 1230.43 (Study 3).

Inclusion criteria differed across the three studies in terms of treatment history. Study 1 (NCT01957644) investigated the combination of volasertib and azacitidine in patients with previously untreated intermediate-2 or higher-risk MDS or CMML, who were not candidates for HSCT. Study 2 (NCT02201329) investigated the combination in Japanese patients with intermediate-2 or higher-risk MDS or CMML, who were also not candidates for HSCT; patients could have previously received treatment with azacitidine or be untreated. Study 3 (NCT02721875) investigated volasertib monotherapy or volasertib plus azacitidine in patients with higher-risk MDS, CMML, or AML after failure of treatment with hypomethylating agents. Other inclusion criteria included: age ≥ 18 years (Studies 1 and 3) or between 20 and 80 (Study 2), Eastern Cooperative Oncology Group performance status (ECOG PS) 0/1 (Study 2), or ≤ 2 (Studies 1 and 3).

Patients were excluded from all three studies if they had received prior treatment with volasertib or had a concomitant malignancy requiring active therapy. Patients in Study 1 were excluded if they had received prior or concomitant therapy for higher-risk MDS or prior treatment with any PLK1 inhibitor. In Study 2, patients were excluded if they had received systemic therapy for MDS within 14 days before treatment. Patients were excluded in Study 3 if they had received any prior systemic therapy for MDS, CMML, or AML within 14 days of treatment, and if they had received any prior PLK inhibitor or hypomethylating treatment.

In all three studies, escalating doses of intravenous volasertib were administered to determine the maximum tolerated doses (MTD); all cycles were 28 days. In Part 1 of Study 1, patients received volasertib infusions on days 1 and 15, starting at a flat dose of 250 mg and escalating in 50 mg steps to 350 mg (Fig. 1). In Part 2 of Study 1, patients received volasertib infusions on days 1, 8, 15, and 22, starting at a flat dose of 250 mg and escalating in 50 mg steps to 350 mg (Fig. 1).
patients received body surface area (BSA)-adapted doses of volasertib and different schedules (Schedule A [planned], volasertib 170 mg/m² on day 1; Schedule B, volasertib 170 mg/m² on day 7; Schedule C, volasertib 110 mg/m² on days 1 and 7). After the MTD was determined, it was planned to enroll up to 40 patients in an expansion cohort to characterize safety further.

In Study 2, a schedule of infusions on days 1 and 15 was planned, starting at a flat dose of 200 mg in Cohort 1 and escalating in 50 mg steps to 300 mg (250 mg in Cohort 2 and 300 mg in Cohort 3). In Study 3, a schedule of infusions on days 1 and 8 was planned, starting at a dose of 110 mg/m² (other doses and another schedule were also planned).

Patients in Studies 1 and 2 also received subcutaneous azacitidine 75 mg/m² on days 1–7 of the 28-day cycle. Study 3 planned to evaluate two different treatment schedules: volasertib monotherapy (Schedule A) and
subcutaneous or intravenous azacitidine in combination with volasertib (Schedule B). The dose escalation cohorts for each Schedule were planned to be enrolled alternately.

All trials were carried out in accordance with the principles of the Declaration of Helsinki, with the International Conference on Harmonization Tripartite Guideline for Good Clinical Practice (GCP), and with applicable regulatory requirements. All patients provided written informed consent.

Endpoints
The primary objective of each study was to determine the MTD of volasertib in combination with azacitidine (or as monotherapy in Study 3), which was defined as the dose level in which less than 2 of 6 patients (Study 1), not more than 1 of 6 patients (Study 2), or not more than 33% of patients (Study 3) experienced a dose-limiting toxicity (DLT).

DLTs were defined as any of the following considered to be drug-related: 1) grade $\geq 3$ (Common Terminology Criteria for Adverse Events [CTCAE] Version 3.0 or 4.03) non-hematological toxicity (exceptions were untreated nausea, vomiting, or diarrhea; clinically non-significant laboratory abnormalities, or laboratory abnormalities that resolved spontaneously; febrile neutropenia or grade 3 infection if the patient recovered with appropriate treatment within 7 days [all studies]); 2) inability to deliver the full dose of volasertib according to the assigned dose level within cycle 1; 3) treatment delay of $\geq 4$ weeks due to drug-related adverse events (DRAEs).

Further safety endpoints included the incidence and intensity of adverse events (AEs) graded according to CTCAE Version 3.0 or Version 4.03. Efficacy was a secondary endpoint in these studies and was assessed by determining objective response to treatment according to International Working Group 2006 criteria [15]. In Studies 1 and 3, the objective response rate was calculated (proportion of patients with complete remission [CR] or partial remission [PR]).

Statistical analyses
All analyses were summarized descriptively; no formal hypothesis testing was planned.

Protocol amendments
Study 1
Following reports of an increased rate of fatal infection in the phase III 1230.14 trial of volasertib in patients with AML, Study 1 was modified: volasertib dosing adaptation to the patient’s individual BSA instead of a volasertib flat starting dose of 250 mg and the introduction of volasertib dosing schedules A (day 1), B (day 7), and C (days 1 and 7) instead of a single dosing schedule (days 1 and 15).

Study 2
In consideration of the DLT occurrence status in Study 1, planned doses in Cohorts 2 and 3 were changed from 300 mg to 250 mg for Cohort 2 and from 350 mg to 300 mg for Cohort 3, with the change of number of patients per cohort from 3-6 to 6, and Cohort Intermediate was deleted.

Study 3
The amendments to the protocol for Study 3 were as follows: the analysis of efficacy was to be performed only for the secondary endpoint because only 1 patient was treated in this study.

Results
Conduct of studies, patients and exposure
Demographic and baseline characteristics were similar across these three studies (Table 1), with a trend for a smaller BSA in Japanese patients (Studies 2 and 3). All patients were white in Study 1 and all patients were of Asian ethnic origin (Japanese) in Studies 2 and 3. In Study 1, 16 patients were treated. In Part 1, 7 patients received volasertib 250 mg plus azacitidine, and 6 patients received volasertib 300 mg plus azacitidine. The median treatment duration was 117 days (range, 2–393 days) and the median number of cycles initiated was 4 cycles (range, 1–10 cycles). In Part 2, 2 patients received Schedule B (volasertib 170 mg/m$^2$ on day 7 and azacitidine 75 mg/m$^2$ on days 1–7). These patients received treatment for 7 and 224 days, and started 1 and 5 cycles, respectively. One patient received Schedule C in Part 2 (volasertib 110 mg/m$^2$ on days 1 and 7 and azacitidine 75 mg/m$^2$ on days 1–7). This patient received treatment for 7 days and initiated 1 cycle. The study was stopped after these 16 patients were treated due to discontinuation of the development of volasertib for non-clinical reasons.

In Study 2, 5 Japanese patients were treated with volasertib 200 mg plus azacitidine, and 6 patients received volasertib 300 mg plus azacitidine. The median treatment duration was 117 days (range, 2–393 days) and the median number of cycles initiated was 4 cycles (range, 1–10 cycles). In Part 2, 2 patients received Schedule B (volasertib 170 mg/m$^2$ on day 7 and azacitidine 75 mg/m$^2$ on days 1–7). These patients received treatment for 7 and 224 days, and started 1 and 5 cycles, respectively. One patient received Schedule C in Part 2 (volasertib 110 mg/m$^2$ on days 1 and 7 and azacitidine 75 mg/m$^2$ on days 1–7). This patient received treatment for 7 days and initiated 1 cycle. The study was stopped after these 16 patients were treated due to discontinuation of the development of volasertib.

In Study 3, 1 patient was treated with volasertib 110 mg/m$^2$ monotherapy but withdrew from the study because of progressive disease (PD). The patient initiated 2 cycles and received four administrations of volasertib. The study was then stopped due to discontinuation of the development of volasertib.
Safety

AEs were reported in all treatment groups across the three studies. The most common AEs were thrombocytopenia and neutropenia (Tables 2 and 3). DLTs reported for volasertib in combination with azacitidine were all grade 4 thrombocytopenia.

### Study 1

In all treatment cycles in Part 1, at least one AE was reported for 12 of 13 patients. The most common AEs were thrombocytopenia (10 patients; 77%) and neutropenia (7 patients; 54%; Table 3). Over all treatment cycles, 10 patients (77%) had at least one grade 4 AE and 2 patients (15%) had at least one grade 3 AE. Three patients (23%) permanently reduced the volasertib dose due to AEs. Eight patients (62%) reported serious AEs (SAEs; Table 2); 2 patients had febrile neutropenia which was classed as an SAE, and 2 patients had pneumonia; the other SAEs were each reported in 1 patient only. Thrombocytopenia (9 patients; 69%), neutropenia (7 patients; 54%), and nausea (5 patients; 38%) were the most common DRAEs (Fig. 2a). In Part 2, the patient on Schedule C had SAEs (sepsis, hypokalemia, and febrile

### Table 1  Baseline and demographic characteristics

|                          | Study 1 Part 1 (n = 13) | Study 1 Part 2 (n = 3) | Study 2 (n = 5) | Study 3 (n = 1) |
|--------------------------|-------------------------|------------------------|----------------|----------------|
| Male/Female, n (%)       | 11 (85)/2 (15)          | 2 (67)/1 (33)          | 3 (60)/2 (40)  | 1 (100)/0      |
| Mean age, years (SD)     | 68.6 (7.7)              | N/A                    | 73.2 (4.6)     | 69 (N/A)       |
| ECOG PS, n (%)           |                         | N/A                    |                |                |
| 0                        | 4 (31)                  |                         | 4 (80)         | 0              |
| 1                        | 7 (54)                  |                         | 1 (20)         | 1 (100)        |
| 2                        | 2 (15)                  |                         | 0              | 0              |
| Disease, n (%)           |                         | N/A                    |                |                |
| MDS                      | 12 (92)                 | 5 (100)                | 0              | 0              |
| CMML                     | 1 (8)                   | 0                      | 0              | 0              |
| AML                      | 0                       | 0                      | 1 (100)        | 0              |
| IPSS classification at screening, n (%) | | | | |
| Int-2 (1.5–2.0)          | 9 (69)                  | 2 (40)                 | 0              | 0              |
| High (≥ 2.5)             | 4 (31)                  |                         | 1 (100)        | 0              |
| Previous treatments, n (%) |                       | N/A                    |                |                |
| No prior treatment       | 11 (85)                 | 1 (20)                 | 0              | 0              |
| Azacitidine              | 0                       | 4 (80)                 | 1 (100)        |                |
| Cytarabine               | 0                       | 1 (20)                 | 0              | 0              |
| Aclarubicin hydrochloride| 0                       | 1 (20)                 | 0              | 0              |
| Growth factor            | 1 (8)                   | 0                      | 0              | 0              |
| Lenalidomide             | 1 (8)                   | 0                      | 0              | 0              |
| Other                    | 2 (15)                  | 0                      | 0              | 0              |
| Median BSA, m² (range)   | 1.9 (1.7–2.2)           | N/A                    | 1.6 (1.4–1.8)  | 1.7 (N/A)      |
| Median body weight, kg (range) | 79.9 (64.2–99.2) | N/A                    | 59.5 (48.0–69.0) | 60.5 (N/A) |

AML, acute myeloid leukemia; BSA, body surface area; CMML, chronic myelomonocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IPSS, international prognostic scoring system; MDS, myelodysplastic syndrome; N/A, data not available; SD, standard deviation

### Table 2  Summary of AEs in Studies 1 (Part 1) and 2 in patients receiving volasertib and azacitidine

|                        | Study 1 Part 1 (n = 13) | Study 2 (n = 5) |
|------------------------|-------------------------|----------------|
| Any AE                 | 12 (92)                 | 5 (100)        |
| DRAE                   | 12 (92)                 | 5 (100)        |
| AE leading to dose reduction of volasertib | 3 (23) | 1 (20) |
| AE leading to dose reduction of azacitidine | 0 | 2 (40) |
| AE leading to discontinuation of trial medication | 6 (46) | 0 |
| SAE                    | 8 (62)                  | 2 (40)         |
| DLT                    | 2 (15)                  | 2 (40)         |
| Worst CTCAE grade      |                         |                |
| Grade 1                | 0                       | 0              |
| Grade 2                | 0                       | 0              |
| Grade 3                | 2 (15)                  | 0              |
| Grade 4                | 10 (77)                 | 5 (100)        |
| Grade 5                | 0                       | 0              |

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; DLT, dose-limiting toxicity; DRAE, drug-related adverse event; SAE, serious adverse event
neutropenia). Two DLTs were reported and both were grade 4 thrombocytopenia; one in the volasertib 250 mg cohort, and one in the volasertib 300 mg cohort. As the study was discontinued, the MTD of volasertib in combination with azacitidine could not be determined.

**Study 2**

In all treatment cycles, at least one AE was reported for all 5 patients (Table 3) and all patients experienced at least one drug-related AE (Table 2). All patients experienced at least one grade 4 AE. No patients experienced AEs leading to discontinuation of study medication. AEs leading to dose reduction of volasertib and azacitidine were reported for 1 and 2 patients, respectively (Table 2). Two of 5 patients in the 200 mg cohort experienced DLTs, both grade 4 thrombocytopenia; hence, the MTD of volasertib on days 1 and 15 of a 28-day cycle in combination with azacitidine for Japanese patients was considered to be < 200 mg. Injection site reaction was the most common DRAE (Fig. 2a).

**Study 3**

The patient with AML who received volasertib monotherapy experienced 18 AEs, none of which were considered by the investigator to be drug-related. One AE was an SAE, grade 3 lower gastrointestinal hemorrhage, which required prolongation of hospitalization. Other grade 3 AEs were injection site infection, pneumonia, and cataracts.

**Efficacy**

Preliminary signs of clinical activity were observed in Studies 1 and 2.

**Study 1**

In Part 1 of Study 1, 2 of the 12 evaluable patients (17%) had CR and 1 (8%) had PR, 6 patients (50%) had marrow CR (mCR), 2 patients (17%) had stable disease (SD), and 1 patient was not evaluable (Fig. 2b). In Part 2, none of the patients had an objective response. One patient had mCR and 2 were not evaluable.

**Study 2**

In Study 2, 2 of the 5 evaluable patients (40%) achieved mCR. One patient (20%) had SD; 1 patient (20%) had PD, and 1 patient (20%) was not evaluable (Fig. 2b). Response durations in the 2 patients with mCR were 221 days and 157 days.

**Study 3**

In Study 3, the patient experienced PD after Cycle 2; no CR, PR, nor hematological improvement were observed during Cycle 1 or 2.

---

**Table 3** Most common adverse events occurring in ≥ 30% of patients receiving volasertib and azacitidine in Studies 1 (Part 1) and 2

| Event                              | Study 1 Part 1 (n = 13) | Study 2 (n = 5) |
|------------------------------------|--------------------------|-----------------|
|                                    | All          | G1 | G2 | G3 | G4 | All | G1 | G2 | G3 | G4 |
| Injection site reaction            | 0            | 0  | 0  | 0  | 0  | 5   | 0  | 0  | 0  | 0  |
| Thrombocytopenia                   | 10 (77)      | 0  | 0  | 2 (15) | 8 (62) | 2 (40) | 0  | 0  | 2 (40) | 0  |
| Neutropenia                        | 7 (54)       | 0  | 1 (8) | 0  | 6 (46) | 1 (20) | 0  | 0  | 0  | 1 (20) |
| Diarrhea                           | 6 (46)       | 5 (39) | 0  | 1 (8) | 0  | 2 (40) | 2 (40) | 0  | 0  | 0  |
| Decreased appetite                 | 6 (46)       | 4 (31) | 2 (15) | 0  | 0  | 1 (20) | 0  | 1 (20) | 0  | 0  |
| Rash                               | 6 (46)       | 5 (39) | 1 (8) | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| Febrile neutropenia                | 2 (15)       | 0  | 0  | 2 (15) | 0  | 2 (40) | 0  | 0  | 2 (40) | 0  |
| Pneumonia                          | 3 (23)       | 0  | 1 (8) | 2 (15) | 0  | 2 (40) | 0  | 1 (20) | 1 (20) | 0  |
| Pharyngitis                        | 3 (23)       | 3 (23) | 0  | 0  | 0  | 2 (40) | 2 (40) | 0  | 0  | 0  |
| White blood cell count decreased   | 0            | 0  | 0  | 0  | 0  | 2 (40) | 0  | 0  | 1 (20) | 1 (20) |
| Hypersensitivity                   | 0            | 0  | 0  | 0  | 0  | 2 (40) | 1 (20) | 1 (20) | 0  | 0  |
| Fatigue                            | 5 (39)       | 2 (15) | 3 (23) | 0  | 0  | 1 (20) | 1 (20) | 0  | 0  | 0  |
| Constipation                       | 5 (39)       | 4 (31) | 0  | 1 (8) | 0  | 1 (20) | 0  | 1 (20) | 0  | 0  |
| Cough                              | 5 (39)       | 5 (39) | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| Nausea                             | 5 (38)       | 4 (31) | 1 (8) | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| Blood creatinine increased         | 4 (31)       | 2 (15) | 2 (15) | 0  | 0  | 0  | 1 (20) | 1 (20) | 0  | 0  |
| Anemia                             | 4 (31)       | 0  | 3 (23) | 1 (8) | 0  | 0  | 1 (20) | 0  | 0  | 1 (20) |
| Vomiting                           | 4 (31)       | 3 (23) | 1 (8) | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| Erythema                           | 4 (31)       | 3 (23) | 1 (8) | 0  | 0  | 0  | 0  | 0  | 0  | 0  |
| Alopecia                           | 4 (31)       | 4 (31) | 0  | 0  | 0  | 0  | 0  | 0  | 0  | 0  |

G grade
Discussion
These three studies were all prematurely discontinued when the clinical development of volasertib was discontinued, following a strategic decision by the sponsor; however, they provide useful insights into the safety profile and preliminary clinical activity of a PLK inhibitor as a treatment for MDS/CMML.

The safety profile of volasertib monotherapy or in combination with azacitidine was assessed in all three studies. All DLTs reported for volasertib in combination with azacitidine were grade 4 thrombocytopenia.

Volasertib, administered as a flat-dosing schedule (250 mg and 300 mg), in combination with azacitidine had a clinically manageable safety profile in Study 1. However, the MTD of volasertib in combination with azacitidine was not determined as the study was discontinued, meaning that only limited data are available on the tolerability of the combination regimen in this study. Of note, Study 1 had a protocol deviation from the 3+3 design. Of the 7 patients who received the 250 mg dosage, 6 were in the escalation phase, and 1 was in expansion phase. Initially, two DLTs were reported at 300 mg and the MTD was determined as 250 mg. Per protocol, recruitment to the MTD extension cohort (250 mg) was opened and 1 patient was enrolled. The study was then modified and Part 2 (BSA-adapted dosing) started. According to the final analysis, the previously concluded MTD of volasertib 250 mg in combination with azacitidine is not valid and it was concluded that one of the two DLTs in the 300 mg cohort did not meet the DLT criteria. Therefore, one DLT was reported in the volasertib 250 mg plus azacitidine cohort, and one was reported in the volasertib 300 mg plus azacitidine dose cohort in the final analysis of Part 1 (i.e. no MTD determined in Part 1).

In Study 2, the starting flat dose of volasertib 200 mg in combination with azacitidine exceeded the MTD in
Japanese patients, and the study was discontinued. In Study 3, only 1 patient was treated with volasertib monotherapy; however, none of the AEs experienced by the patient were considered drug-related by the investigator.

The safety profile of volasertib in all studies was in line with previous studies [11, 12, 16]; the most common DRAEs, and all DLTs, were hematological in nature. Thrombocytopenia and neutropenia worsening was reported on treatment. However, as the cardinal symptoms of MDS patients are cytopenias, the symptoms of the underlying disease and the hematologic effects of volasertib (myelosuppression and cytopenias) are not distinguishable. Therefore, detection of the expected hematologic adverse effects of volasertib is challenging in MDS patients.

In Study 1, no MTD was determined up to a dose of 300 mg volasertib in combination with azacitidine. However, in Study 2, the dose of 200 mg volasertib in combination with azacitidine exceeded the MTD. This discrepancy might be explained by the difficulty to distinguish the symptoms of the underlying disease and the hematologic effects of treatment. Tolerability may have also been impacted by different patient characteristics (body weight, BSA) in Studies 1 and 2, due to a trend for a more pronounced myelosuppressive effect in patients with a lower weight.

To improve the tolerability of volasertib in combination with azacitidine in patients with MDS, BSA-based dosing and modified timing of administration to extend the treatment recovery period were investigated. However, the effect of these measures could not be assessed because the studies were terminated prematurely.

Preliminary signs of efficacy were observed in Studies 1 and 2, but these may have been due to the proven clinical activity of azacitidine alone, as documented in previous published studies [17–19]. Of note, most patients in Study 2 were previously treated with azacitidine; therefore, if these patients were refractory to azacitidine, the efficacy results may possibly be attributed to volasertib. Nevertheless, no firm conclusions on the clinical activity of volasertib plus azacitidine in MDS, CMML, or AML can be drawn from the small number of patients in these uncontrolled studies, especially as the efficacy assessments were not primary endpoints. Another limitation of the study is the absence of molecular data at baseline.

Conclusions
Although these studies were halted for non-clinical reasons, the results presented in this article suggest that a tolerable dose of volasertib, administered in combination with azacitidine, could have been identified for the treatment of patients with MDS/CMML.

Abbreviations
AE: Adverse event; AML: Acute myeloid leukemias; BSA: Body surface area; CMML: Chronic myelomonocytic leukemias; CR: Complete remission; CTCAE: Common Terminology Criteria for Adverse Events; D: Day; DLT: Dose-limiting toxicity; DRAE: Drug-related adverse event; GCP: Good Clinical Practice; HCTC: Hematological stem cell transplantation; LDAC: Low-dose cytarabine; MDS: Myelodysplastic syndromes; MCR: Marrow CR; MTD: Maximum tolerated doses; PD: Progressive disease; PLK: Polo-like kinases; PR: Partial remission; SAE: Serious adverse event; SD: Stable disease.

Code availability
Not applicable.

Authors’ contributions
UP contributed to conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing. JC contributed to collection and assembly of data, data analysis and interpretation, drafting the manuscript. JK contributed to collection and assembly of data, drafting the manuscript. SS contributed to conception and design, data analysis and interpretation, manuscript writing. HH contributed to collection and assembly of data, data analysis and interpretation, drafting the manuscript. WM contributed to collection and assembly of data, data analysis and interpretation, manuscript writing. WS contributed to conception and design, collection and assembly of data, data analysis and interpretation, drafting the manuscript. TT contributed to conception and design, data analysis and interpretation, drafting the manuscript, manuscript writing. YM contributed to conception and design, data analysis and interpretation, drafting the manuscript, manuscript writing. YG contributed to conception and design, collection and assembly of data, drafting the manuscript. UP contributed to conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing. All authors approved the final version of the manuscript and provided final approval to submit the manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: funding by Boehringer Ingelheim. The authors received no direct compensation related to the development of the manuscript.

Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Hannah Simmons MSc, of Ashfield MedComms, an Ashfield Health company, and funded by Boehringer Ingelheim.

Availability of data and materials
To ensure independent interpretation of clinical study results and enable authors to fulfill their role and obligations under the ICMJE criteria, Boehringer Ingelheim grants all external authors access to relevant clinical study data. In adherence with the Boehringer Ingelheim Policy on Transparency and Publication of Clinical Study Data, scientific and medical researchers can request access to clinical study data after publication of the primary manuscript in a peer-reviewed journal, regulatory activities are complete and other criteria are met. Researchers should use the https://vivli.org/ link to request access to study data and visit https://www.mystudywindow.com/msw/datasharing for further information.

Declarations
Ethics approval and consent to participate
The trial was carried out in accordance with the principles of the Declaration of Helsinki, the International Council for Harmonisation Harmonised Tripartite Guideline for Good Clinical Practice, applicable regulatory requirements and Boehringer Ingelheim standard operating procedures. Written informed consent was obtained from all individual participants included in the study.

Consent for publication
Patients signed informed consent regarding publishing their data.
Competing interests
Uwe Platzbecker received grant support, paid to GWT-TUD, from Amgen; lecture fees, grant support, paid to the University of Leipzig; fees for serving on a steering committee, consulting fees, and travel support from Celgene; grant support, paid to GWT-TUD; from Janssen Biotech; grant support, paid to University Dresden, from Merck and Novartis; and lecture fees from Novartis. Joerg Chronik declares no potential conflict of interest. Jan Kronke reports being part of an advisory council or committee for Janssen, Takeda, and Celgene/Bristol-Myers Squibb; received honoraria from Sanofi. Hiroshi Handa received honoraria from Janssen, Takeda, Celgene, Novartis, Ono, AbbVie, and Kyowa-Kirin; consulting fees from Janssen, Takeda, Celgene, and AbbVie; grants or funds from Takeda, Celgene, Novartis, Ono, AbbVie, Kyowa-Kirin, and Chugai. Stephen Strickland received consulting fees (in the past two years) from AbbVie, ArcherDx, Genentech, Incyte, Kura Oncology, Novartis, Pfizer, and Syros. Yasushi Miyazaki received honoraria from AbbVie, Novartis, Astellas, Synbio, Sumitomo-Dainippon, Chugai, Celgene, Nippon-shinyaku, Ohtsuka, and Kyowa-Kirin; and grants or funds from Sumitomo-Dainippon, and Chugai. Martin Wermke received honoraria from Bristol-Myers Squibb, Merck, Roche, Novartis, Kite, Boehinger Ingelheim, and AstraZeneca; consulting or advisory role fees from Bristol-Myers Squibb, Novartis, Kite, Heidelberg Pharma, Roche, and Boehinger Ingelheim; travel, accommodation, expenses from Glenmark, Bristol-Myers Squibb, and AstraZeneca. Wataru Sakamoto is an employee of Nippon Boehinger Ingelheim Co., Ltd. Yoshifumi Tachibana is an employee of Nippon Boehinger Ingelheim. Tillmann Taube is an employee of Boehinger Ingelheim International. Ulrich Germigh received speaker’s honorarium from Celgene, Novartis, and Jazz; consulting fees from Celgene; and institutional research support from Celgene, and Novartis.

Author details
1 Medical Clinic and Polyclinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Johannisallee 32, D-04103 Leipzig, Germany. 2 Department of Hematology and Medical Oncology, University Hospital Frankfurt, Frankfurt, Germany. 3 Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany. 4 Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan. 5 Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. 6 Department of Hematology, Nagasaki University Hospital, Nagasaki City, Japan. 7 NCT/UCC Early Stage Drug Discovery Program, Maebashi, Japan. 8 Clinical Operations Japan, Nippon Boehinger Ingelheim, Tokyo, Japan. 9 Clinical Operations Japan, Nippon Boehinger Ingelheim, Tokyo, Japan. 10 Therapeutic Area Oncology Medicine, Boehinger Ingelheim International, Biberach, Germany. 11 Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany.

Received: 13 January 2022 Accepted: 29 April 2022 Published online: 21 May 2022

References
1. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47. https://doi.org/10.1182/blood-2016-08-733196.
2. Itzykson R, Fenaux P, Bowen D, Cross NC, Fenaux P, Cortes J, et al. Diagnosis and treatment of chronic myelomonocytic leukemia in adults: recommendations from the European Hematology Association and the European LeukemiaNet. Hemasphere. 2018;2:e150. https://doi.org/10.1053/j.hem.2018.05.000.
3. Platzbecker U. Treatment of MDS. Blood. 2019;133:1096–107. https://doi.org/10.1182/blood-2018-10-846966.
4. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, et al. BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res. 2009;15:3094–102. https://doi.org/10.1158/1078-0432.CCR-08-2445.
5. Diesch J, Zwick A, Garz A-K, Palau A, Busheck M, Götzke KS. A clinical-molecular update on azacitidine-based therapy for the treatment of hematologic cancers. Clin Epigenet. 2016;8:21. https://doi.org/10.1186/s13148-016-0237-y.
6. Fenaux P, Haase D, Sanz GF, Santin V, Buske C, Group EGW. Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):i57–69. https://doi.org/10.1093/annonc/mdu180.
7. Wang H, Li Y, Lu N, Li Y, Wang L, Yu L. Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes. Ann Hematol. 2018;97:2025–38. https://doi.org/10.1007/s00277-018-3464-9.
8. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Seitleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291–9. https://doi.org/10.1182/blood-2015-03-621664.
9. Gil-Perez A, Montalban-Bravo G. Management of myelodysplastic syndromes after failure of response to hypomethylating agents. Ther Adv Hematol. 2019;10:204602701987059. https://doi.org/10.1177/204602701987059.
10. Rudolph D, Impagnatello MA, Blaukopf C, Sommer C, Gerlich DW, Roth M, et al. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of polo-like kinases, in preclinical models of acute myeloid leukemia. J Pharmacol Exp Ther. 2015;352:579–89. https://doi.org/10.1124/jpet.114.221150.
11. Ottmann OG, Muller-Tidow C, Kramer A, Schlenk RF, Lubbert M, Bug G, et al. Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia. Br J Haematol. 2019;184:1018–21. https://doi.org/10.1111/bjh.15204.
12. Dohner H, Lubbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014;124:426–33. https://doi.org/10.1182/blood-2014-03-560557.
13. Dohner H, Symeonidis A, Sanz MA, Deeren D, Demeter J, Anastopolous A, et al. Phase III randomized trial of volasertib plus low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated AML, ineligible for intensive therapy. Haematologica. 2016;101(Suppl 1):185–6.
14. Oncoheroes Biosciences Inc. Oncoheroes Biosciences Inc. and Boehinger Ingelheim International GmbH sign exclusive licensing agreements for volasertib. 2019. https://oncoheroe.com/press-releases-content/2019/9/11/oncoheroes-biosciences-inc-and-boehringer-ingelheim-international-gmbh-sign-exclusive-licensing-agreement-for-volasertib. Accessed 18 June 2021.
15. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–25. https://doi.org/10.1182/blood-2005-10-4149.
16. Kobayashi Y, Yamauchi T, Kiyoi H, Sakuta T, Hata A, Ando K, et al. Phase I trial of volasertib, a polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia. Cancer Sci. 2015;106:1590–5. https://doi.org/10.1111/cas.12814.
17. Silverman LR, Demaskos EP, Peterson BL, Kornblith AB, Holland JC, Oddimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–40. https://doi.org/10.1200/jco.2002.04.117.
18. Silverman LR, McKenzie DR, Peterson BL, Holland JC, Backstrom JT, Beach CL, et al. Further analysis of trials of azacitidine in patients with myelodysplastic syndrome: studies 8421, 8201, and 9221 by the Cancer and leukemia group B. J Clin Oncol. 2006;24:3895–903. https://doi.org/10.1200/jco.2005.05.4346.
19. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase II study. Lancet Oncol. 2009;10:223–32. https://doi.org/10.1016/s1470-2045(09)70038-8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.